Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Ann Oncol ; 14(9): 1430-7, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-12954584

RESUMO

BACKGROUND: Pegylated liposomal doxorubicin (Doxil) has been reported to cause immediate hypersensitivity reactions (HSRs) that cannot be explained as IgE-mediated (type I) allergy. Previous in vitro and animal studies indicated that activation of the complement (C) system might play a causal role in the process, a proposal that has not been tested in humans to date. PATIENTS AND METHODS: Patients with solid tumors (n = 29) treated for the first time with Doxil were evaluated for HSRs and concurrent C activation. HSRs were classified from mild to severe, while C activation was estimated by serial measurement of plasma C terminal complex (SC5b-9) levels. Increases in SC5b-9 were compared in patients with or without reactions, and were correlated with Doxil dose rate. RESULTS: Moderate to severe HSRs occurred in 45% of patients. Plasma SC5b-9 at 10 min after infusion was significantly elevated in 92% of reactor patients versus 56% in the non-reactor group, and the rise was greater in reactors than in non-reactors. We found significant association between C activation and HSRs, both showing direct correlation with the initial Doxil dose rate. CONCLUSIONS: C activation may play a key role in HSRs to Doxil. However, low-level C activation does not necessarily entail clinical symptoms, highlighting the probable involvement of further, as yet unidentified, amplification factors.


Assuntos
Antibióticos Antineoplásicos/efeitos adversos , Ativação do Complemento/efeitos dos fármacos , Doxorrubicina/efeitos adversos , Hipersensibilidade a Drogas/imunologia , Hipersensibilidade Imediata/imunologia , Adulto , Idoso , Relação Dose-Resposta a Droga , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias/tratamento farmacológico
2.
J Liposome Res ; 12(1-2): 165-72, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12604051

RESUMO

Pegylated liposomal doxorubicin (Doxil) and 99mTc-HYNIC PEG liposomes (HPL) were reported earlier to cause hypersensitivity reactions (HSRs) in a substantial percentage of patients treated i.v. with these formulations. Here we report that (1) Doxil, HPL, pegylated phosphatidylethanolamine (PEG-PE)-containing empty liposomes matched with Doxil and HPL in size and lipid composition, and phosphatidylglycerol (PG)-containing negatively charged vesicles were potent C activators in human serum in vitro, whereas small neutral liposomes caused no C activation. (2) Doxil and other size-matched PEG-PE and/or PG-containing liposomes also caused massive cardiopulmonary distress with anaphylactoid shock in pigs via C activation, whereas equivalent neutral liposomes caused no hemodynamic changes. (3) A clinical study showed more frequent and greater C activation in patients displaying HSR than in non-reactive patients. These data suggest that liposome-induced HSRs in susceptible individuals may be due to C activation, which, in turn, is due to the presence of negatively charged PEG-PE in these vesicles.


Assuntos
Ativação do Complemento , Lipossomos/metabolismo , Polietilenoglicóis/metabolismo , Animais , Antibióticos Antineoplásicos/administração & dosagem , Antibióticos Antineoplásicos/farmacologia , Doxorrubicina/administração & dosagem , Doxorrubicina/farmacologia , Humanos , Metabolismo dos Lipídeos , Neoplasias/metabolismo , Polietilenoglicóis/farmacologia , Suínos , Tecnécio/farmacologia , Fatores de Tempo
3.
Int Immunopharmacol ; 1(4): 721-35, 2001 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11357884

RESUMO

We reported earlier that the anticancer drug paclitaxel (Taxol) activated the complement (C) system in human serum in vitro, raising the possibility that C activation might play a role in the ill-understood hypersensitivity reactions (HSRs) to this drug [J. Natl. Cancer Inst. 90 (1998) 300]. In pursuing the mechanism of C activation by Taxol, the present study provided evidence that dilution of the injection concentrate in aqueous solvents led to the formation of micelles and needle-like structures, both of which caused C activation in vitro. Micelles were formed mainly from Cremophor EL (CrEL), the nonionic emulsifier vehicle of paclitaxel, whose level in Taxol infusion exceeded its critical micelle concentration by at least 400-fold. CrEL micelles were shown by quasi-elastic light scattering and cryo-transmission electron microscopy (cryo-TEM) to be spherical with diameters in the 8-22 nm range; however, de novo formation of 50-300 nm microdroplets following incubation with human plasma suggested further fundamental structural transformation in blood. The needle-like structures extended to the multimicron range and were shown by electron diffraction to be crystalline paclitaxel. Taxol-induced C activation was manifested in varying rises of serum C3a-desarg, iC3b and SC5b-9. The causal role of CrEL micelles in C activation was demonstrated by the fact that filtration of aqueous solutions of Taxol or pure CrEL via 30-kDa cutoff filters eliminated, while the filter retentate restored C activation. C activation by Taxol was also inhibited by 10 mg/ml human immunoglobulin (IVIG). If proven clinically, HSRs to Taxol may represent a hitherto vaguely classified adverse drug reaction recently called C activation-related pseudoallergy (CARPA) [Circulation 99 (1999) 2302].


Assuntos
Antineoplásicos Fitogênicos/efeitos adversos , Ativação do Complemento/efeitos dos fármacos , Hipersensibilidade a Drogas/etiologia , Paclitaxel/efeitos adversos , Complexo de Ataque à Membrana do Sistema Complemento/análise , Glicerol/administração & dosagem , Glicerol/análogos & derivados , Humanos , Imunoglobulinas Intravenosas/farmacologia , Micelas , Paclitaxel/administração & dosagem , Soluções
4.
Am J Physiol Heart Circ Physiol ; 279(3): H1319-28, 2000 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-10993799

RESUMO

Intravenous injection of liposomes can cause significant pulmonary hypertension in pigs, a vasoconstrictive response that provides a sensitive model for the cardiopulmonary distress in humans caused by some liposomal drugs. The reaction was recently shown to be a manifestation of "complement activation-related pseudoallergy" (CARPA; Szebeni J, Fontana JL, Wassef NM, Mongan PD, Morse DS, Dobbins DE, Stahl GL, Bünger R, and Alving CR. Circulation 99: 2302-2309, 1999). In the present study we demonstrate that the composition, size, and administration method of liposomes have significant influence on pulmonary vasoactivity, which varied between instantaneously lethal (following bolus injection of 5 mg lipid) to nondetectable (despite infusion of a 2,000-fold higher dose). Experimental conditions augmenting the pulmonary hypertensive response included the presence of dimyristoyl phosphatidylglycerol, 71 mol% cholesterol, distearoyl phosphatidylcholine, and hemoglobin in liposomes, increased vesicle size and polydispersity, and bolus injection vs. slow infusion. The vasoactivity of large multilamellar liposomes was reproduced with human C3a, C5a, and xenoreactive immunoglobulins, and it correlated with the complement activating and natural antibody binding potential of vesicles. Unilamellar, monodisperse liposomes with 0.19 +/- 0.10 microm mean diameter had no significant vasoactivity. These data indicate that liposome-induced pulmonary hypertension in pigs is multifactorial, it is due to natural antibody-triggered classic pathway complement activation and it can be prevented by appropriate tailoring of the structure and administration method of vesicles.


Assuntos
Ativação do Complemento/imunologia , Hipersensibilidade a Drogas/imunologia , Hipertensão Pulmonar/imunologia , Lipossomos/imunologia , Animais , Anticorpos/metabolismo , Colesterol/química , Colesterol/farmacologia , Ativação do Complemento/efeitos dos fármacos , Complemento C3a/administração & dosagem , Complemento C5a/administração & dosagem , Dimiristoilfosfatidilcolina/química , Dimiristoilfosfatidilcolina/farmacologia , Relação Dose-Resposta a Droga , Hipersensibilidade a Drogas/metabolismo , Feminino , Humanos , Hipertensão Pulmonar/induzido quimicamente , Hipertensão Pulmonar/metabolismo , Hipertensão Pulmonar/prevenção & controle , Imunoglobulinas Intravenosas/administração & dosagem , Infusões Intravenosas , Injeções Intravenosas , Modelos Lineares , Lipossomos/administração & dosagem , Lipossomos/efeitos adversos , Lipossomos/química , Masculino , Tamanho da Partícula , Fosfatidilcolinas/química , Fosfatidilcolinas/farmacologia , Fosfatidilgliceróis/química , Fosfatidilgliceróis/farmacologia , Suínos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA